Valuation: Wakamoto Pharmaceutical Co.,Ltd.

Market Cap 9.43B 59.86M 53.61M 49.31M 44.68M 83.52M 5.68B 85.08M 588M 236M 2.99B 225M 220M P/E 2011
-20.8x
P/E 2012 -38.7x
Enterprise Value 9.22B 58.51M 52.4M 48.2M 43.68M 81.64M 5.56B 83.17M 575M 231M 2.92B 220M 215M EV / Sales 2011
0.9x
EV / Sales 2012 0.89x
Free-Float
55.74%
Yield 2011 *
-
Yield 2012 -
1 day+1.00%
1 week+1.68%
Current month+1.00%
1 month+1.00%
3 months+13.06%
6 months-13.18%
Current year+5.94%
1 week 296
Extreme 296
305
1 month 289
Extreme 289
306
Current year 240
Extreme 240
380
1 year 240
Extreme 240
380
3 years 189
Extreme 189
380
5 years 189
Extreme 189
380
10 years 188
Extreme 188
754
Manager TitleAgeSince
President 61 -
Corporate Officer/Principal 59 2005-06-30
Corporate Officer/Principal 58 2007-05-31
Director TitleAgeSince
Director/Board Member 72 2017-05-31
Director/Board Member 70 2009-05-31
Director/Board Member 61 2019-06-20
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%+1.68%+5.21%+56.19% 66.93M
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.66%+5.48%+42.45%+80.44% 426.2B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%

Financials

2011 2012
Net sales 9.67B 61.39M 54.98M 50.57M 45.82M 85.65M 5.83B 87.25M 603M 242M 3.07B 230M 225M 9.43B 59.88M 53.63M 49.33M 44.7M 83.55M 5.69B 85.11M 588M 236M 2.99B 225M 220M
Net income -425M -2.7M -2.42M -2.22M -2.01M -3.76M -256M -3.84M -26.51M -10.64M -135M -10.13M -9.91M -222M -1.41M -1.26M -1.16M -1.05M -1.97M -134M -2M -13.85M -5.56M -70.39M -5.29M -5.18M
Net Debt -156M -990K -887K -816K -739K -1.38M -94.04M -1.41M -9.73M -3.91M -49.47M -3.72M -3.64M -212M -1.35M -1.21M -1.11M -1M -1.88M -128M -1.91M -13.22M -5.31M -67.22M -5.05M -4.94M
Logo Wakamoto Pharmaceutical Co.,Ltd.
WAKAMOTO PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of ethical drugs such as gastrointestinal drugs and non-prescription drugs. The Company operates through four business segments. The Pharmaceuticals segment is involved in the manufacture and sale of innovator drugs, generic drugs and optiaid series supplements mainly in the ophthalmic field, as well as the commission of production and the sale of diagnostic drugs and raw materials in Japan. The Healthcare segment sales its core product Kawakami Wakamoto, the Avantbise series of medicated toothpastes that promote bad breath prevention based on evidence and Avantbise Oral Tablet mainly in the mail order business. The International segment is involved in the business related to the export of products and raw materials mainly in Asia and Europe, as well as the new license in and out business. The Real Estate Leasing segment is involved in the rental business of Coredo Muromachi.
Employees
403
Date Price Change Volume
26-10-30 JP¥303.00 +1.00% 16,800
26-10-29 JP¥300.00 0.00% 6,800
26-10-28 JP¥300.00 -0.99% 2,800
26-10-27 JP¥303.00 +1.00% 27,100
26-10-26 JP¥300.00 +0.67% 4,300
  1. Stock Market
  2. Stocks
  3. 4512 Stock